HERO Trial (Hunger Elimination or Reduction Objective)
ARD-101 is an investigational orally delivered small-molecule for the treatment of hyperphagia-related behavior in Prader-Willi Syndrome (PWS). We believe ARD-101’s unique ability to induce gut-localized CCK and GLP-1 secretion could result in a reduction in hyperphagia-related behaviors.
